RE: Hepatic Splentic gamma-Delta T-cell Lymphoma

Maryalice Stetler-Stevenson (stetler@box-s.nih.gov)
Wed, 28 May 1997 11:04:17 -0400

In the NIH experience, the only survivor had a bone marrow transplant. It
is a really bad disease with a fairly rapid demise.

Maryalice

>From: Witzig, Thomas E., M.D. Subject: RE: Hepatic Splentic gamma-Delta T-cell
>Lymphoma
>
>I have had some experience with this entity and we are writing up the Mayo
>cases seen so far. Unfortunately, its an aggressive disease. There are no
>known protocols - its really too rare for a protocol. I'd recommend: 1. An
>adriamycin containing regimen such as CHOP, CDE infusional (actually ECOG does
>have this open as a protocol and the patient could probably enter it --its for
>aggressive NHL not specifically gamma-delta), ProMACECytaBOM
>
>2. If responsive, I'd check the blood and marrow and transplant if clean. 3.
>If not a transplant candidate and does not get a CR with regimen in #1 then
>I'd try a platinum regimen OR 2-deoxycoformycin- Pentostatin (good for T-cell
>processes and commercially available and usually outpatient and
>well-tolerated.
>
>
>Sincerely,
>
>Tom Witzig (witzig.thomas@mayo.edu)

Maryalice Stetler-Stevenson
Director Flow Cytometry Unit
Laboratory of Pathology, NCI, NIH


Home Page Table of Contents Sponsors E-Mail Archive Web Sites

CD-ROM Vol 3 was produced by Monica M. Shively and other staff at the Purdue University Cytometry Laboratories and distributed free of charge as an educational service to the cytometry community. If you have any comments please direct them to Dr. J. Paul Robinson, Professor & Director, PUCL, Purdue University, West Lafayette, IN 47907. Phone: (765)-494-0757; FAX(765) 494-0517; Web http://www.cyto.purdue.edu , EMAIL cdrom3@flowcyt.cyto.purdue.edu